Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 14564311)

1.
2.

Role of inflammatory mediators in the pathogenesis of epilepsy.

Shimada T, Takemiya T, Sugiura H, Yamagata K.

Mediators Inflamm. 2014;2014:901902. doi: 10.1155/2014/901902. Epub 2014 Aug 13. Review.

3.

Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

Malmström RE, Godman BB, Diogene E, Baumgärtel C, Bennie M, Bishop I, Brzezinska A, Bucsics A, Campbell S, Ferrario A, Finlayson AE, Fürst J, Garuoliene K, Gomes M, Gutiérrez-Ibarluzea I, Haycox A, Hviding K, Herholz H, Hoffmann M, Jan S, Jones J, Joppi R, Kalaba M, Kvalheim C, Laius O, Langner I, Lonsdale J, Lööv SÄ, Malinowska K, McCullagh L, Paterson K, Markovic-Pekovic V, Martin A, Piessnegger J, Selke G, Sermet C, Simoens S, Tulunay C, Tomek D, Vončina L, Vlahovic-Palcevski V, Wale J, Wilcock M, Wladysiuk M, van Woerkom M, Zara C, Gustafsson LL.

Front Pharmacol. 2013 May 14;4:39. doi: 10.3389/fphar.2013.00039. eCollection 2013.

4.

Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?

Brunnekreef JJ, Hoogervorst P, Ploegmakers MJ, Rijnen WH, Schreurs BW.

Int Orthop. 2013 Apr;37(4):583-7. doi: 10.1007/s00264-013-1781-0. Epub 2013 Jan 29.

5.

Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention.

Rao CV, Janakiram NB, Mohammed A.

Curr Colorectal Cancer Rep. 2012 Dec;8(4):316-324.

6.

Aging, metabolic syndrome and the heart.

Veronica G, Esther RR.

Aging Dis. 2012 Jun;3(3):269-79. Epub 2012 Mar 13.

7.

Promoting transparency in pharmaceutical industry-sponsored research.

Ross JS, Gross CP, Krumholz HM.

Am J Public Health. 2012 Jan;102(1):72-80. doi: 10.2105/AJPH.2011.300187. Epub 2011 Nov 28.

8.

Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety.

Roth SH.

Clin Interv Aging. 2011;6:125-31. doi: 10.2147/CIA.S21107. Epub 2011 May 30. Review.

9.

RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.

Strillacci A, Griffoni C, Valerii MC, Lazzarini G, Tomasi V, Spisni E.

J Biomed Biotechnol. 2010;2010:828045. doi: 10.1155/2010/828045. Epub 2010 Jun 13. Review.

10.

Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM.

Arch Intern Med. 2009 Nov 23;169(21):1976-85. doi: 10.1001/archinternmed.2009.394.

11.

Myricetin and quercetin are naturally occurring co-substrates of cyclooxygenases in vivo.

Bai HW, Zhu BT.

Prostaglandins Leukot Essent Fatty Acids. 2010 Jan;82(1):45-50. doi: 10.1016/j.plefa.2009.10.006. Epub 2009 Nov 7.

12.

Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.

Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D.

Br J Clin Pharmacol. 2006 Jun;61(6):730-7. Erratum in: Br J Clin Pharmacol. 2007 May;63(5):635.

13.

Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs.

Lu D, Cottam HB, Corr M, Carson DA.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18567-71. Epub 2005 Dec 13.

14.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk